José Angel Cigarroa López
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
José Angel Cigarroa López has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Aide Alejandra Toledo-González
Instituto Mexicano del Seguro Social, Centro Médico Nacional Siglo XXI, Hospital de Cardiología, Servicio de Laboratorio Clínico. Ciudad de México, México
1 shared publication Cecilia Camacho-Hubner
Former Pfizer Global and Regional Medical Lead, Rare Disease, New York City, New York, United States of America
1 shared publicationClaudenice Leite Bertoli de Souza
Pfizer, São Paulo, Brazil
1 shared publication- Constanza Otero
Real World Insights, IQVIA, Chile, Santiago
1 shared publication Diana Buitrago
Real World Insights, IQVIA, Colombia, Bogotá
1 shared publicationDiego Pérez de Arenaza
Head of Cardiovascular Imaging, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
1 shared publication
Latest Publications
- Open Access
- 26 June 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (6) , e0351224
Awareness, attitudes, and barriers toward Transthyretin Amyloid Cardiomyopathy in Latin America: A questionnaire-based cross-sectional study
Background: Cardiac Amyloidosis (CA), specifically Transthyretin Amyloid Cardiomyopathy (ATTR-CM), is an under-recognized, progressive, and fatal disease. Comprehensive primary data describing awareness, attitudes, and barriers to treatment in Latin America (LATAM) are lacking, highlighting a gap between guidelines and real-world clinical practice. Methods: A cross-sectional, questionnaire-based observational study was conducted among 470 physicians actively involved in patient management across 8 LATAM countries (June-August 2023). The study assessed their awareness, attitudes, and barriers concerning ATTR-CM. Descriptive analysis was performed. Results: Limited knowledge of ATTR-CM was observed. Awareness of its pathophysiology was reported by 50.2%. Patients consulted 4–5 physicians before receiving a confirmed diagnosis. Cardiologists managed most day-to-day cases (76.2%). Transthyretin genetic testing was available to only 26.4%. Local treatment protocols relied on international guidelines (87.4%), with Real-World Data considered important by 60.6%. Patient cost and access to tafamidis were frequently reported barriers. Follow-up commonly relied on echocardiography, NT-pro BNP, NYHA classification, and ECG/Holter ECG. Conclusions: Difficulties in ATTR-CM diagnosis and management in LATAM were influenced by varying knowledge levels, gaps in diagnostic algorithms, and significant access barriers. These factors contribute to delayed diagnosis and management. Enhanced, tailored training strategies and collaborative efforts are necessary to improve early diagnosis, effective treatment, and ultimately, patient outcomes in the region.
- 26 June 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (6) , e0351224
Open AccessAwareness, attitudes, and barriers toward Transthyretin Amyloid Cardiomyopathy in Latin America: A questionnaire-based cross-sectional study
Background: Cardiac Amyloidosis (CA), specifically Transthyretin Amyloid Cardiomyopathy (ATTR-CM), is an under-recognized, progressive, and fatal disease. Comprehensive primary data describing awareness, attitudes, and barriers to treatment in Latin America (LATAM) are lacking, highlighting a gap between guidelines and real-world clinical practice. Methods: A cross-sectional, questionnaire-based observational study was conducted among 470 physicians actively involved in patient management across 8 LATAM countries (June-August 2023). The study assessed their awareness, attitudes, and barriers concerning ATTR-CM. Descriptive analysis was performed. Results: Limited knowledge of ATTR-CM was observed. Awareness of its pathophysiology was reported by 50.2%. Patients consulted 4–5 physicians before receiving a confirmed diagnosis. Cardiologists managed most day-to-day cases (76.2%). Transthyretin genetic testing was available to only 26.4%. Local treatment protocols relied on international guidelines (87.4%), with Real-World Data considered important by 60.6%. Patient cost and access to tafamidis were frequently reported barriers. Follow-up commonly relied on echocardiography, NT-pro BNP, NYHA classification, and ECG/Holter ECG. Conclusions: Difficulties in ATTR-CM diagnosis and management in LATAM were influenced by varying knowledge levels, gaps in diagnostic algorithms, and significant access barriers. These factors contribute to delayed diagnosis and management. Enhanced, tailored training strategies and collaborative efforts are necessary to improve early diagnosis, effective treatment, and ultimately, patient outcomes in the region.
- Open Access
- 5 February 2024
- Vol. 62 (suppl 1) , 1-9
[Blood transfusion in patients undergoing heart transplant surgery].
In patients undergoing cardiac surgery, one of the most common complications is bleeding. There are risk factors associated with bleeding and transfusion during or after cardiac surgery. The decision of blood transfusion depends on the individualized characteristics of each patient. To determine the characteristics that influenced blood transfusion, aside from the frequency and proportion of the use of blood components. We identified patients who underwent heart transplant surgery and the frequency of those who required transfusion. The proportion of the use of blood components, the characteristics of the surgical intervention and factors that influenced transfusion and mortality were determined. We included 19 patients who underwent heart transplant surgery. 89.5% received blood transfusion. The mean amount of blood products used during surgery and hospitalization was 2.10 red blood cells, 1.10 fresh frozen plasma and 0.89 apheresis platelets. The odds ratio for transfusion in surgery was 1.4 for mortality. 89.5% of the patients required blood transfusion either in surgery (73.7%) or during hospitalization (68.4%). Age, cardiopulmonary bypass time, and length of stay represented risk for transfusion. Age over 45 years and transfusion in hospitalization increase the risk of mortality.
- 5 February 2024
- Vol. 62 (suppl 1) , 1-9
Open Access[Blood transfusion in patients undergoing heart transplant surgery].
In patients undergoing cardiac surgery, one of the most common complications is bleeding. There are risk factors associated with bleeding and transfusion during or after cardiac surgery. The decision of blood transfusion depends on the individualized characteristics of each patient. To determine the characteristics that influenced blood transfusion, aside from the frequency and proportion of the use of blood components. We identified patients who underwent heart transplant surgery and the frequency of those who required transfusion. The proportion of the use of blood components, the characteristics of the surgical intervention and factors that influenced transfusion and mortality were determined. We included 19 patients who underwent heart transplant surgery. 89.5% received blood transfusion. The mean amount of blood products used during surgery and hospitalization was 2.10 red blood cells, 1.10 fresh frozen plasma and 0.89 apheresis platelets. The odds ratio for transfusion in surgery was 1.4 for mortality. 89.5% of the patients required blood transfusion either in surgery (73.7%) or during hospitalization (68.4%). Age, cardiopulmonary bypass time, and length of stay represented risk for transfusion. Age over 45 years and transfusion in hospitalization increase the risk of mortality.